Sorafenib Plus Ixabepilone as First-Line Treatment for Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase 1/2 Trial
Yardley, Denise A., MD, Dickson, Natalie, MD, Drosick, David, MD, Earwood, Chris, Inhorn, Roger, MD, Murphy, Patrick, MD, Hainsworth, John D., MD
Published in Clinical breast cancer (2016)
Published in Clinical breast cancer (2016)
Get full text
Journal Article